Skip to main content
. 2019 Jul 9;8:212590. doi: 10.7573/dic.212590

Table 1.

Summary of novel biologics in AAD.

Mechanism of action Indications Administration
Omalizumab Anti-IgE

  • Severe persistent asthma (>6 years)

  • Chronic idiopathic urticaria (>12 years)

 Subcutaneously q2 or q4 weeks (dosage depending on weight and IgE levels)
Ligelizumab Anti-IgE

  • Chronic urticaria (phase III >12 years)

  • Allergic asthma (phase II >18 years)

 Subcutaneously q2 weeks (240 mg)
Mepolizumab Anti-IL5

  • Severe refractory eosinophilic asthma (>6 years)

  • Churg–Strauss syndrome (registered)

 Subcutaneously every 4 weeks (100 mg ≥12 years; 40 mg 6–11 years)
Benralizumab Anti-IL5 receptor

  • Severe refractory eosinophilic asthma (>18 years)

 Subcutaneously (30 mg q4 weeks for the first three doses, q8 weeks thereafter)
Reslizumab Anti-IL5

  • Severe refractory eosinophilic asthma (>18 years)

 Intravenous infusion q4 weeks (dosage depending on weight)
Dupilumab Anti-IL4 and IL-13

  • Moderate-to-severe atopic dermatitis (>18 years)

  • Severe refractory eosinophilic asthma

Subcutaneously q week (first dose 600 mg then 300 mg)